Faegre Drinker Biddle & Reath LLP, a Delaware limited liability partnership | This website contains attorney advertising.

Health Care & Life Sciences Consulting

Overview

As a stakeholder in the health and life sciences industry, you work every day to extend the boundaries of human health and enhance patient care. With a bipartisan team of lobbyists and public policy professionals, we partner with you to advance this mission through effective coalition management, strategic communications, and strong relationships with decision-makers at the state and federal levels. We promote the public policy and advocacy agendas of hospitals and health systems, academic medical centers, medical device and life science companies, patient advocacy organizations, membership trade associations, health professional societies, and global health groups. With our guidance, clients author and enact legislation; establish new policies and programs; navigate and shape regulatory processes; secure and maintain Medicare reimbursement for new products and technologies; defeat proposals that threaten their priorities; and take action to safeguard their interests. We build bridges with agencies such as the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA) to help clients secure funding and support for their projects, campaigns, and research initiatives. Our team unites diverse stakeholders in coalitions aligned under shared policy goals, develops politically viable policy solutions that advance client goals, and builds awareness and support through grassroots advocacy. We’ve helped clients shape legislative, executive branch, and regulatory activity at the highest level.

Faegre Drinker Consulting professionals do not act as attorneys for clients. Learn more about the Faegre Drinker Consulting practice.

Insights & Events

Insights
Updates March 2026

Access through Innovation with Amazon Pharmacy

Digital Health “From the Inside Out” Leadership Series
2 min read
Updates March 2026

FDA Finalizes Rule Requiring 12-Digit National Drug Code (NDC)

Two Little Digits, One Very Big Operational Headache
4 min read
Updates February 2026

FDA Publishes Long-Awaited Draft Guidance on “Plausible Mechanism Framework” to Spur the Development of New Individualized Medicines

Anticipated Deadline for Comments Is April 27, 2026
7 min read
Media Mentions January 2026

Nick Manetto Discusses Future of Federal PBM Spread Pricing Bill With Inside Health Policy

1 min read
Media Mentions January 2026

Megan Herber and Nisha Quasba Discuss Reintroduction of NSGC’s Genetic Counseling Bill

2 min read
Updates November 2025

What Does the Agreement to Reopen the Federal Government Mean for Health Policy Interests?

And What Opportunities May Lie Ahead?
5 min read
Updates November 2025

SCOTUS Weighs Trump Administration’s Tariff Authority Under IEEPA; Pharma and Device AI; and More

Biopharma & Medical Devices Briefing
7 min read
Media Mentions October 2025

Libby Baney Comments on Uncertainty in Prescription Drug Market With the Washington Post

1 min read
Published Articles October 2025

Defining Child Health Research to Guide Equitable Federal Appropriations

Journal of Pediatrics
1 min read
Published Articles October 2025

'Most-Favored Nation' Drug Pricing: Impacts on the Pharmacy Supply Chain

National Association of Boards of Pharmacy’s Innovations
1 min read

Meet The Team

Meet The Full Health Care & Life Sciences Consulting Team